Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRPK1 | Q96SB4 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | SRPK2 | P78362 | 1/20 | 1.00 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | TEK | Q02763 | 4/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110544 | 1.00 | SRPK1 (1.00) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL3485927 | 1.00 | SRPK1 (1.00) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL3485920 | 0.99 | SRPK1 (0.98) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL1110642 | 0.89 | SRPK1 (0.80) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL13540499 | 0.88 | SRPK1 (0.79) | SRPK1KDRSRPK2SRPK3ALDH1A1 | |
| SCHEMBL12765717 | 0.88 | SRPK1 (0.78) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL3485129 | 0.88 | SRPK1 (0.78) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL3485680 | 0.88 | POLB (0.81) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL1110612 | 0.87 | SRPK1 (0.77) | SRPK1KDRSRPK2SRPK3MAPT | |
| SCHEMBL20198561 | 0.87 | KDR (0.77) | SRPK1KDRSRPK2SRPK3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053809-A1 | MOLECULAR THERAPEUTIC STRATEGY COMBINING IDELALISIB AND SRPIN340 TO TREAT ADVANCE SOLID TUMORS | UNIV OF MARYLAND EASTERN SHORE (US) | 2026-02-26 | — | — | US | claimed |
| EP-4361136-A1 | COMPOUND FOR THE TREATMENT OF GLIOBLASTOMA | Universidad De Córdoba (ES) | 2024-05-01 | — | — | EP | claimed |
| US-20220380765-A1 | TARGETING NONSENSE-MEDIATED DECAY TO ACTIVATE P53 PATHWAY FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-12-01 | — | — | US | claimed |
| US-11499197-B2 | Prognosis method of multiple myeloma | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-11-15 | — | — | US | claimed |
| EP-3432886-B1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2021-06-02 | — | — | EP | claimed |
| US-10842785-B2 | PIM kinase inhibitors in combination with RNA splicing modulators/inhibitors for treatment of cancers | THE UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2020-11-24 | — | — | US | claimed |
| US-20200046689-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2020-02-13 | — | — | US | claimed |
| US-20190076416-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIV MARYLAND (US) | 2019-03-14 | — | — | US | claimed |
| EP-3432886-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | University of Maryland, Baltimore County (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165495-A1 | PIM KINASE INHIBITORS IN COMBINATION WITH RNA SPLICING MODULATORS/INHIBITORS FOR TREATMENT OF CANCERS | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2017-09-28 | — | — | WO | claimed |
| EP-4048809-B1 | SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY | TEMPUS AI INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4729940-A2 | LARGE SCALE ORGANOID ANALYSIS | Tempus AI, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260053809-A1 | MOLECULAR THERAPEUTIC STRATEGY COMBINING IDELALISIB AND SRPIN340 TO TREAT ADVANCE SOLID TUMORS | UNIV OF MARYLAND EASTERN SHORE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260053809-A1 | MOLECULAR THERAPEUTIC STRATEGY COMBINING IDELALISIB AND SRPIN340 TO TREAT ADVANCE SOLID TUMORS | UNIV OF MARYLAND EASTERN SHORE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260053809-A1 | MOLECULAR THERAPEUTIC STRATEGY COMBINING IDELALISIB AND SRPIN340 TO TREAT ADVANCE SOLID TUMORS | UNIV OF MARYLAND EASTERN SHORE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| CN-1921885-A | Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient | HAGIWARA MASATOSHI (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1712242-A1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA, Masatoshi (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | SRPK1, SARS1, SRPK3 | SRPK1 1/4885KDR 2410/4885SRPK2 4/4885 |
| US-20260053809-A1 | MOLECULAR THERAPEUTIC STRATEGY COMBINING IDELALISIB AND SRPIN340 TO TREAT ADVANCE SOLID TUMORS | PIK3R4, SRPK3, PIK3R5 | SRPK1 4/4885KDR 1523/4885SRPK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.